| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
Form 4: Fmr Llc, 10% owner
Sold 175,000 shares ($5.09M) · Sold 53,454 shares ($1.61M) |
| 12 Nov 2026 | 10-Q |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Initiated Phase 1 study of AP03, a fixed dose combination of nebulized pirfenidone and nintedanib, in healthy volunteers |
| 17 Sep 2026 |
Form 4: Meyer Robert J., Director
Granted 31,182 Stock Option (Right to Buy) |
| 17 Sep 2026 |
Form 3: Meyer Robert J., Director
No securities owned |
| 16 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On September 15, 2026 (the “Effective Date”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Avalyn Pharma Inc. (the “Company”), the Board appointed Robert Meyer, M... |
| 14 Aug 2026 | SCHEDULE 13G |
| 12 Aug 2026 | 10-Q |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027 |
| 11 Aug 2026 | SCHEDULE 13G |
| 06 Aug 2026 | SCHEDULE 13G/A |
| 01 Jul 2026 |
8-K: Entry into a Material Definitive Agreement
THIS FIRST AMENDMENT TO SUBLEASE (this “Amendment”) is made and entered into as of June 29, 2026 (the “Effective Date”), by and between CRISPR THERAPEUTICS, INC., a Delaware corporation, with a place of business at 105 West First Street,... |
| 17 Jun 2026 |
8-K: Regulation FD Disclosure
Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis |
| 03 Jun 2026 | 10-Q |
| 03 Jun 2026 |
8-K: Results of Operations and Financial Condition
On track to complete enrollment of MIST Phase 2b trial of AP01 in progressive pulmonary fibrosis (PPF) in mid-2026, with newly presented long term open-label extension clinical data that support favorable tolerability profile |
| 08 May 2026 | SCHEDULE 13D |
| 08 May 2026 | SCHEDULE 13D |
| 07 May 2026 | SCHEDULE 13G |
| 05 May 2026 |
Form 4: Novo Holdings A/S, 10% owner
Received 3,327,734 shares by conversion · Bought 555,555 shares ($10M) |
| 05 May 2026 | SCHEDULE 13G |
Loading...